You need to be logged in to see the full monograph.

TOBACCO AND NICOTINE REPLACEMENT THERAPY (NRT) USE IN PREGNANCY

Date of issue: April 2026, Version: 2

bumps logo
A corresponding patient information leaflet on TOBACCO AND NICOTINE REPLACEMENT THERAPY (NRT) USE IN PREGNANCY is available.

Pregnant women and those planning a pregnancy should be advised and supported to stop smoking. Tobacco smoking during pregnancy is associated with increased risks of miscarriage, infant congenital malformation, stillbirth, premature delivery, intrauterine growth restriction and placental abruption. Smoking in pregnancy is also associated with sudden infant death and other adverse offspring outcomes, such as neurodevelopmental disorders, asthma, obesity, diabetes, and cancer.

Traditional NRT products (gums, sublingual tablets, inhalators, lozenges, oromucosal/nasal sprays and transdermal patches) are recommended first-line in the UK by NICE for smoking cessation during pregnancy. E-cigarettes (vapes) are not recommended as NRT for pregnant women in the UK due to limited fetal safety data compared to traditional NRT. However, some smoking cessation charities and the NHS pragmatically advise that, where traditional NRT is declined or has been ineffective, use of e-cigarettes during pregnancy, although not without health risks, may be preferable to smoking. For more information about e-cigarette use (vaping) in pregnancy, please see the separate monograph.

Published human pregnancy NRT exposure data do not provide robust evidence of increased risks of adverse pregnancy outcomes, whereas the risks associated with smoking in pregnancy are well-established.

Exposure to traditional NRT at any stage in pregnancy would not usually be regarded as medical grounds for termination of pregnancy or any additional fetal monitoring. Pregnant women who are enrolled in smoking cessation programmes may be offered some additional monitoring at antenatal appointments. Women who have smoked heavily during later pregnancy may be offered additional fetal growth monitoring. Other risk factors which independently increase the risk of adverse pregnancy outcome, or for which enhanced follow-up is required, may be present in individual women. Clinicians are reminded of the importance of considering such factors when performing case-specific risk assessments.

This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to NHS health care professionals who are logged in.

If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.

If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.

Disclaimer: Every effort has been made to ensure that this monograph was accurate and up-to-date at the time of writing, however it cannot cover every eventuality and the information providers cannot be held responsible for any adverse outcomes of the measures recommended. The final decision regarding which treatment is used for an individual patient remains the clinical responsibility of the prescriber. This material may be freely reproduced for education and not for profit purposes within the UK National Health Service, however no linking to this website or reproduction by or for commercial organisations is permitted without the express written permission of this service. This document is regularly reviewed and updated. Only use UKTIS monographs downloaded directly from UKTIS.org to ensure you are using the most up-to-date version.